Pfizer Independent Medical Education RFP

Improving Care for Patients with Multiple Myeloma

Competitive Grant Program – Pfizer Internal Review Process

Overview

This competitive program seeks to provide educational grants to US-based organizations to support continuing education projects focused on the evolving treatment landscape for patients with relapsed/refractory multiple myeloma (RRMM).

Geographic Scope

United States

Project Types and Area of Interest

Applicants are encouraged to identify and address the educational needs, barriers, and gaps related to the care of patients with RRMM and the use of bispecific therapies. Proposed activities should focus on increasing clinicians’ knowledge, confidence, competence and practice changes in caring for patients with RRMM. This may include interactive learning, case-based learning, workshops, tumor boards, digital platforms, visiting professors, mentorships, building communities of practice, live programs.

Key Milestones

- Application submission deadline: October 16, 2023
- Anticipated decision notification date: November 17, 2023
- Anticipated project start date: January 1, 2024

Funding Range and Project Length

Requests up to $200,000 will be considered. Total funding available for this RFP is $1,000,000. Project should launch between Q1-Q2 2024 and the duration should be 12-15 months.
I. Eligibility

Geographic Scope:
- United States

Applicant Eligibility Criteria
- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- The following may apply: **US based** medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); **US based** non-profit professional organizations/medical societies; and other **US-based** non-profit entities with a mission related to healthcare professional education and/or healthcare improvement. **US based** medical education companies and for-profit organizations are welcomed to submit, however non-profit professional organizations/medical societies and medical schools/institution will be prioritized.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead's grant coordinator).
- The project/program lead must be an employee or independent contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

II. Requirements

Date RFP Issued:
- September 19, 2023

Clinical Area:
- Relapsed/Refractory Multiple Myeloma

Target Audience:
- Academic & Community hematologists/oncologists, oncology nurses, oncology NP/PAs, oncology pharmacists
- Emergency physicians, neurologists, infectious disease physicians, and primary care providers

General Area of Interest for this RFP:
The goal of this RFP is to support education targeting academic and community hematologists, oncologists, nurse practitioners, physician assistants, and pharmacists working in the oncology setting. Additionally, this RFP seeks to support education targeting the nuanced needs of Emergency Department clinicians, neurologists, infectious disease physicians, and primary care providers involved in the care of patients with RRMM treated with bispecific antibodies.
Please ensure your statement of need justifies the type of education being proposed and is aligned to the needs of the proposed target audience. Projects that will be considered for Pfizer support will focus on addressing the educational needs and identified gaps for bispecific antibodies in relapsed/refractory multiple myeloma. The areas of interest include:

- MM diagnosis and referral to appropriate specialist
- Product handling and administration
- Transition of care from inpatient to outpatient
- Available clinical data and insights into efficacy, dosing, and side effect profile
- Risk factors for development of treatment specific adverse events (AEs), identification of these AEs, and therapy management strategies
- Overview of experiences and potential sequencing of bispecific antibodies

We are also interested in raising awareness of disparities of care and opportunities to improve the quality and equitable access to MM treatment across diverse and underrepresented patient populations. Proposed activities should focus on increasing clinicians' knowledge, confidence, competence and practice changes in caring for patients with RRMM. Activity formats that will be considered under this RFP include interactive learning, case-based learning, workshops, tumor boards, digital platforms, visiting professors, mentorships, projects to build communities of practice, live programs. Requests from professional organizations and other non-profit organizations reaching healthcare providers will be prioritized.

*It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.*

**Expected Approximate Monetary Range of Grant Applications:**

- Individual projects requesting up to $200,000 will be considered. Projects greater than $200,000 may be considered for exceptional proposals with detailed budget justification. The estimated total available budget related to this RFP is $1,000,000
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

**Key Dates:**

- RFP release date: **September 19, 2023**
- Grant Application due date: **October 16, 2023**
  Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: **November 17, 2023**
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: **January 1, 2024** to **April 1, 2025**
How to Submit:
Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
  - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
  - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
  - Select the following Competitive Grant Program Name: 2023 ONC US Improving MM Care IME
  - Select the following Primary Area of Interest: Oncology – Hematologic
- Requirements for submission:
  - Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
  - If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed.

Questions:
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Kaczerski (amanda.kaczerski@pfizer.com), with the subject line “2023 ONC US Improving MM Care IME September 2023.”

Grant Agreements:
- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process:
- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:
- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.
About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Appendix

General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives
- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project
- Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience
- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods
- Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation
- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes
- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan
- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline
- Provide an anticipated timeline for your project including project start/end dates.
Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.

- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details.